×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
ARQT – arcutis biotherapeutics, inc. - common stock (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
ARQT
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
3/23
12:46 am
arqt
Arcutis Biotherapeutics (ARQT) Valuation Check After New Pediatric ZORYVE Phase 3 Extension Data [Yahoo! Finance]
Low
Report
Arcutis Biotherapeutics (ARQT) Valuation Check After New Pediatric ZORYVE Phase 3 Extension Data [Yahoo! Finance]
3/18
05:41 pm
arqt
Arcutis (ARQT) Announces Long-Term Phase 3 Data for ZORYVE Cream in Children [Yahoo! Finance]
Low
Report
Arcutis (ARQT) Announces Long-Term Phase 3 Data for ZORYVE Cream in Children [Yahoo! Finance]
3/18
08:00 am
arqt
Arcutis to Present New Clinical Data in a Late-Breaking Podium Presentation and Scientific Posters at the 2026 American Academy of Dermatology Annual Meeting
Medium
Report
Arcutis to Present New Clinical Data in a Late-Breaking Podium Presentation and Scientific Posters at the 2026 American Academy of Dermatology Annual Meeting
3/10
09:25 am
arqt
Arcutis Announces Publication of Positive Long-Term Safety and Efficacy Data with ZORYVE® (roflumilast) Cream 0.05% for Treatment of Mild-to-Moderate Atopic Dermatitis in Children Ages 2–5 in Pediatric Dermatology [Yahoo! Finance]
Low
Report
Arcutis Announces Publication of Positive Long-Term Safety and Efficacy Data with ZORYVE® (roflumilast) Cream 0.05% for Treatment of Mild-to-Moderate Atopic Dermatitis in Children Ages 2–5 in Pediatric Dermatology [Yahoo! Finance]
3/10
09:00 am
arqt
Arcutis Announces Publication of Positive Long-Term Safety and Efficacy Data with ZORYVE® (roflumilast) Cream 0.05% for Treatment of Mild-to-Moderate Atopic Dermatitis in Children Ages 2–5 in Pediatric Dermatology
Low
Report
Arcutis Announces Publication of Positive Long-Term Safety and Efficacy Data with ZORYVE® (roflumilast) Cream 0.05% for Treatment of Mild-to-Moderate Atopic Dermatitis in Children Ages 2–5 in Pediatric Dermatology
3/6
07:03 pm
arqt
Guggenheim Raises Its Price Target on Arcutis Biotherapeutics, Inc. (ARQT) to $35 and Maintains a Buy Rating [Yahoo! Finance]
Medium
Report
Guggenheim Raises Its Price Target on Arcutis Biotherapeutics, Inc. (ARQT) to $35 and Maintains a Buy Rating [Yahoo! Finance]
3/5
11:25 am
arqt
A Look At Arcutis Biotherapeutics (ARQT) Valuation After New ARQ 234 Trial Milestone [Yahoo! Finance]
Low
Report
A Look At Arcutis Biotherapeutics (ARQT) Valuation After New ARQ 234 Trial Milestone [Yahoo! Finance]
3/5
09:28 am
arqt
Arcutis Announces Promotion of Mas Matsuda to Executive Vice President and Chief Legal Officer to Support Next Phase of Growth [Yahoo! Finance]
Low
Report
Arcutis Announces Promotion of Mas Matsuda to Executive Vice President and Chief Legal Officer to Support Next Phase of Growth [Yahoo! Finance]
Date
Time
Symbol
Company Name
Action
%Chg
2/25/2026
04:00 pm
arqt
arcutis biotherapeutics, inc. - common stock
BEAT
Report
5.8%
arcutis biotherapeutics, inc. - common stock
10/28/2025
08:30 am
arqt
arcutis biotherapeutics, inc. - common stock
BEAT
Report
18.3%
arcutis biotherapeutics, inc. - common stock
8/6/2025
04:00 pm
arqt
arcutis biotherapeutics, inc. - common stock
BEAT
Report
-8.1%
arcutis biotherapeutics, inc. - common stock
5/6/2025
04:00 pm
arqt
arcutis biotherapeutics, inc. - common stock
BEAT
Report
-4.3%
arcutis biotherapeutics, inc. - common stock
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
3/4
04:18 pm
arqt
Form 4 Arcutis Biotherapeutics, For: Mar 02 Filed by: Leonard Keith R
Low
Report
Form 4 Arcutis Biotherapeutics, For: Mar 02 Filed by: Leonard Keith R
3/4
04:16 pm
arqt
Form 4 Arcutis Biotherapeutics, For: Mar 02 Filed by: Welgus Howard G.
Low
Report
Form 4 Arcutis Biotherapeutics, For: Mar 02 Filed by: Welgus Howard G.
3/3
08:43 pm
arqt
Form 4 Arcutis Biotherapeutics, For: Feb 27 Filed by: Edwards Larry Todd
Low
Report
Form 4 Arcutis Biotherapeutics, For: Feb 27 Filed by: Edwards Larry Todd
3/3
08:43 pm
arqt
Form 4 Arcutis Biotherapeutics, For: Feb 27 Filed by: Watanabe Todd
Low
Report
Form 4 Arcutis Biotherapeutics, For: Feb 27 Filed by: Watanabe Todd
3/3
08:42 pm
arqt
Form 4 Arcutis Biotherapeutics, For: Feb 27 Filed by: Matsuda Masaru
Low
Report
Form 4 Arcutis Biotherapeutics, For: Feb 27 Filed by: Matsuda Masaru
3/3
08:42 pm
arqt
Form 4 Arcutis Biotherapeutics, For: Feb 27 Filed by: Vairavan Latha
Low
Report
Form 4 Arcutis Biotherapeutics, For: Feb 27 Filed by: Vairavan Latha
3/3
08:42 pm
arqt
Form 4 Arcutis Biotherapeutics, For: Aug 18 Filed by: Burnett Patrick
Low
Report
Form 4 Arcutis Biotherapeutics, For: Aug 18 Filed by: Burnett Patrick
3/2
06:49 pm
arqt
Form 144 Arcutis Biotherapeutics, Filed by: Matsuda Masaru
Medium
Report
Form 144 Arcutis Biotherapeutics, Filed by: Matsuda Masaru
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
3/19
Form 10-K Arcutis Biotherapeutics, For: Dec 31
33.3%
1/31 Form 424B4 Arcutis Biotherapeutics, 15.3%
3/23 I-Mab (NASDAQ: ARQT) had its "buy" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $50.00 price target on the stock. 11.4%
2/6 Form 4 Arcutis Biotherapeutics, For: Feb 04 Filed by: Koppel Adam 6.7%
2/19 Arcutis to Present at the Cowen 40th Annual Health Care Conference 4.3%
4/21 Arcutis Announces Enrollment of First Patient in Phase 1/2b Study of ARQ-252 in Patients with Chronic Hand Eczema 3.4%
2/3 Form 4 Arcutis Biotherapeutics, For: Jan 30 Filed by: TURNER JOSEPH L 3.1%
2/7 Form SC 13D Arcutis Biotherapeutics, Filed by: Bain Capital Life Sciences Fund, L.P. 2.9%
2/6 Form 4 Arcutis Biotherapeutics, For: Feb 04 Filed by: Heron Patrick J 2.4%
2/13 Arcutis Announces Enrollment of First Patient in Topical Roflumilast Cream Phase 3 Open Label Extension Study in Plaque Psoriasis 2.3%
1/31 Form 424B4 Arcutis Biotherapeutics, 15.3%
3/23 I-Mab (NASDAQ: ARQT) had its "buy" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $50.00 price target on the stock. 11.4%
2/6 Form 4 Arcutis Biotherapeutics, For: Feb 04 Filed by: Koppel Adam 6.7%
2/19 Arcutis to Present at the Cowen 40th Annual Health Care Conference 4.3%
4/21 Arcutis Announces Enrollment of First Patient in Phase 1/2b Study of ARQ-252 in Patients with Chronic Hand Eczema 3.4%
2/3 Form 4 Arcutis Biotherapeutics, For: Jan 30 Filed by: TURNER JOSEPH L 3.1%
2/7 Form SC 13D Arcutis Biotherapeutics, Filed by: Bain Capital Life Sciences Fund, L.P. 2.9%
2/6 Form 4 Arcutis Biotherapeutics, For: Feb 04 Filed by: Heron Patrick J 2.4%
2/13 Arcutis Announces Enrollment of First Patient in Topical Roflumilast Cream Phase 3 Open Label Extension Study in Plaque Psoriasis 2.3%
TOP News Decliners
3/16
Arcutis Announces Inclusion of Children in On-going Pivotal Phase 3 Clinical Trials Evaluating Topical Roflumilast (ARQ-151) as a Potential Once Daily Topical Treatment for Plaque Psoriasis
-16.2%
1/31 Form S-8 Arcutis Biotherapeutics, -5.4%
2/25 I-Mab (NASDAQ: ARQT) is now covered by analysts at Cantor Fitzgerald. They set an "overweight" rating and a $50.00 price target on the stock. -4.6%
4/27 Form 8-K Arcutis Biotherapeutics, For: Apr 23 -2.7%
2/28 Form SEC STAFF LETTER Arcutis Biotherapeutics, -2.0%
2/4 Form 4 Arcutis Biotherapeutics, For: Feb 04 Filed by: Watanabe Todd Franklin -1.6%
2/10 Form SC 13D Arcutis Biotherapeutics, Filed by: ORBIMED ADVISORS LLC -1.0%
3/4 Form 4 Arcutis Biotherapeutics, For: Feb 27 Filed by: Sun Ricky -0.3%
1/31 Form S-8 Arcutis Biotherapeutics, -5.4%
2/25 I-Mab (NASDAQ: ARQT) is now covered by analysts at Cantor Fitzgerald. They set an "overweight" rating and a $50.00 price target on the stock. -4.6%
4/27 Form 8-K Arcutis Biotherapeutics, For: Apr 23 -2.7%
2/28 Form SEC STAFF LETTER Arcutis Biotherapeutics, -2.0%
2/4 Form 4 Arcutis Biotherapeutics, For: Feb 04 Filed by: Watanabe Todd Franklin -1.6%
2/10 Form SC 13D Arcutis Biotherapeutics, Filed by: ORBIMED ADVISORS LLC -1.0%
3/4 Form 4 Arcutis Biotherapeutics, For: Feb 27 Filed by: Sun Ricky -0.3%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: